Ascendis Pharma A/S (ASND) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 8.8% versus a loss of 12.8%. Over five years, ASND leads with a +42.8% price change compared with -7.6% for RDY. Ascendis Pharma A/S is the larger company by market cap ($14.65 billion vs $10.16 billion), about 1.4 times the size.
On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (18.9x vs 20.6x for Ascendis Pharma A/S). Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Ascendis Pharma A/S does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | RDY |
|---|---|---|
| Share price | $222.69 | $12.20 |
| Market cap | $14.65B | $10.16B |
| 1-day change | -2.50% | -0.57% |
| YTD return | +7.11% | -13.11% |
| 1-year return | +8.84% | -12.79% |
| 5-year return | +42.77% | -7.59% |
| P/E ratio (TTM) | 17.06 | 27.73 |
| Forward P/E | 20.58 | 18.94 |
| EPS (TTM) | $13.05 | $0.44 |
| Dividend yield | 0.00% | 65.57% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | — | $3.81B |
| Revenue growth (YoY) | — | +13.76% |
| Net income (latest FY) | — | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | — | 22.09% |
| Net margin | — | 17.40% |
| 52-week high | $282.15 | $15.67 |
| 52-week low | $186.05 | $11.36 |
| Distance from 52-week high | -21.07% | -22.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +37.34% | +8.36% |
| Average volume | 658.78K | 2.89M |
| Shares outstanding | 65.80M | 832.99M |
| Employees | 1,189 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASND has outperformed RDY by 21.6 percentage points over the past year.
- Dr. Reddy's Laboratories trades at a higher earnings multiple (27.7x vs 17.1x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.57% vs 0.00%).
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
ASND vs RDY FAQ
Which is bigger, Ascendis Pharma A/S or Dr. Reddy's Laboratories?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $14.65B compared with $10.16B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, ASND or RDY?
ASND returned +8.84% over the past 12 months, compared with -12.79% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or RDY?
ASND has the lower trailing P/E at 17.1, versus 27.7 for RDY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Ascendis Pharma A/S or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Ascendis Pharma A/S does not currently pay a regular dividend.
Are Ascendis Pharma A/S and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.